Pamela M. McInnes Named National Center for Advancing Translational Sciences Deputy Director
Pamela M. McInnes, DDS, has been named deputy director of the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health. McInnes currently serves as director of the Division of Extramural Research at the National Institute of Dental and Craniofacial Research (NIDCR). She will join NCATS in January 2014.
“I am thrilled that Pamela is joining the NCATS leadership team. Her expertise in translational and clinical research coupled with her extensive extramural management experience, and her record of accomplishment in trans-NIH and public-private collaborations, make her an ideal fit as our deputy director,” said NCATS Director Christopher P. Austin, MD. “Her recruitment is a key milestone in our building the NCATS organisation into a catalyst for transformational change in translational science, getting new treatments to more patients more quickly.”
At NIDCR, McInnes was responsible for all of the institute’s extramural research, which ranges from basic through clinical research, including large and complex clinical and population-based trials. She is committed to the rigorous and robust conduct of clinical trials that adhere to the highest standards for human subject protection and data integrity. Her work in translational sciences has led to numerous product development and clinical evaluation programmes, and she is involved actively with the broader extramural research community in efforts to reduce morbidity and mortality attributable to a large spectrum of diseases and disorders.
“I am excited to join NCATS, which is uniquely focused on solving translational process problems that aren’t a primary focus of disease-oriented programmes,” McInnes said. “I look forward to collaborating with stakeholders in the government, academia, patient organisations and the private sector to revolutionise the way translational research is conducted nationwide.”
Prior to her time at NIDCR, McInnes spent 16 years at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), where she served in many capacities, including deputy director for its Division of Microbiology and Infectious Diseases. In this role, she oversaw extramural research branch programs in infectious diseases and microbiology. She concurrently served as associate director for clinical research and had responsibility for the reorganisation and oversight of the complex and diverse Divisional Clinical Research Program. Her work on contract awards to develop recombinant RPA anthrax vaccines and attenuated smallpox vaccines required extensive collaboration and interactions with the Food and Drug Administration, Department of Defense, and Centers for Disease Control and Prevention.
Another of her many accomplishments at NIAID was oversight of the scientific design and programmatic implementation of its Challenge Grant Program. The goal of this initiative was to promote joint ventures between NIH and biotechnology, pharmaceutical and medical device industries to reduce significantly the impact of infectious diseases nationally and worldwide.
The author of more than 40 peer-reviewed articles and five books, McInnes first joined NIH in 1989 as a grants associate for its Office of Extramural Programs in the Office of the Director. Before coming to NIH, she served in academic and consulting roles at the Louisiana State University Medical Center, Shreveport. McInnes earned her DDS and MS degrees from the University of the Witwatersrand, in Johannesburg, where she also lectured prior to coming to the US.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance